CABA - Cabaletta Bio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Philadelphia,
United States
Type: Equity
CABA price evolution
CABA
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $178.61 | $175.29 | $193.24 | |
| Short term investments | $24.61 | $48.55 | $48.01 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $185.51 | $206.26 | $227.48 | $244.49 |
| Long term investments | ||||
| Property, plant & equipment | $16.41 | $8.91 | $10.61 | $7.45 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $11.16 | $12.98 | $9.16 | |
| Total investments | $24.61 | $48.55 | $48.01 | |
| Total assets | $204.41 | $217.42 | $240.46 | $253.65 |
| Current liabilities | ||||
| Accounts payable | $2.18 | $4.22 | $5.84 | $4.55 |
| Deferred revenue | ||||
| Short long term debt | $7.4 | $7.4 | $3.56 | |
| Total current liabilities | $22.88 | $17.9 | $17.97 | $15.99 |
| Long term debt | $0.77 | $1.46 | ||
| Total noncurrent liabilities | $0.77 | $1.46 | ||
| Total debt | $7.4 | $8.17 | $5.02 | |
| Total liabilities | $30.17 | $17.9 | $18.74 | $17.45 |
| Shareholders' equity | ||||
| Retained earnings | -$316.51 | -$285.89 | -$258.28 | -$233.24 |
| Other shareholder equity | $0 | -$0.03 | -$0.04 | $0.04 |
| Total shareholder equity | $199.52 | $221.72 | $236.2 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $193.24 | $81.61 | $122.22 | $101.43 |
| Short term investments | $48.01 | $24.94 | $7.23 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $244.49 | $108.83 | $124.54 | $113.53 |
| Long term investments | ||||
| Property, plant & equipment | $7.45 | $7.57 | $1.44 | $0.89 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.16 | $8.13 | $1.79 | $1.19 |
| Total investments | $48.01 | $24.94 | $7.23 | |
| Total assets | $253.65 | $116.97 | $126.34 | $114.72 |
| Current liabilities | ||||
| Accounts payable | $4.55 | $2.46 | $2.33 | $1.24 |
| Deferred revenue | ||||
| Short long term debt | $3.56 | $2.18 | ||
| Total current liabilities | $15.99 | $9.49 | $8.38 | $5.18 |
| Long term debt | $1.46 | $2.96 | ||
| Total noncurrent liabilities | $1.46 | $2.96 | ||
| Total debt | $5.02 | $5.14 | ||
| Total liabilities | $17.45 | $12.45 | $8.38 | $5.18 |
| Shareholders' equity | ||||
| Retained earnings | -$233.24 | -$165.56 | -$112.59 | -$66.3 |
| Other shareholder equity | $0.04 | -$0.05 | -$0 | $0.01 |
| Total shareholder equity | $236.2 | $104.52 | $117.96 | $109.54 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $23.43 | $21.95 | $17.41 | |
| Selling, general & administrative | $6.85 | $6.08 | $5.74 | |
| Total operating expenses | $33.05 | $30.28 | $28.03 | $23.15 |
| Operating income | -$30.28 | -$28.03 | -$23.15 | |
| Income from continuing operations | ||||
| EBIT | -$27.6 | -$25.05 | -$20.89 | |
| Income tax expense | ||||
| Interest expense | $2.42 | |||
| Net income | ||||
| Net income | -$30.63 | -$27.6 | -$25.05 | -$20.89 |
| Income (for common shares) | -$27.6 | -$25.05 | -$20.89 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $55.42 | $39.3 | $32.49 | $21.38 |
| Selling, general & administrative | $19.24 | $14.84 | $13.82 | $12.46 |
| Total operating expenses | $74.66 | $54.14 | $46.31 | $33.83 |
| Operating income | -$74.66 | -$54.14 | -$46.31 | -$33.83 |
| Income from continuing operations | ||||
| EBIT | -$67.67 | -$52.98 | -$46.29 | -$33.34 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$67.67 | -$52.98 | -$46.29 | -$33.34 |
| Income (for common shares) | -$67.67 | -$52.98 | -$46.29 | -$33.34 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$27.6 | -$25.05 | -$20.89 | |
| Operating activities | ||||
| Depreciation | $2.18 | $1.82 | $1 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.01 | $3.79 | $3.05 | |
| Total cash flows from operations | -$20.79 | -$23.99 | -$16.45 | |
| Investing activities | ||||
| Capital expenditures | -$0.77 | -$0.81 | -$0.18 | |
| Investments | $24.5 | $1.32 | ||
| Total cash flows from investing | $35.16 | $23.73 | -$0.81 | $1.14 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.38 | $6.86 | $93.05 | |
| Net borrowings | ||||
| Total cash flows from financing | $7.3 | $0.38 | $6.86 | $93.05 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.63 | $3.32 | -$17.95 | $77.74 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$67.67 | -$52.98 | -$46.29 | -$33.34 |
| Operating activities | ||||
| Depreciation | $3.5 | $3.68 | $0.73 | $0.35 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.34 | $6.9 | $5.8 | $4.39 |
| Total cash flows from operations | -$53.55 | -$46.38 | -$34.11 | -$26.77 |
| Investing activities | ||||
| Capital expenditures | -$0.69 | -$2.45 | -$1.17 | -$0.64 |
| Investments | -$21.76 | -$24.76 | $7.17 | -$7.35 |
| Total cash flows from investing | -$22.45 | -$27.22 | $6 | -$7.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $187.63 | $32.98 | $48.9 | -$0.02 |
| Net borrowings | ||||
| Total cash flows from financing | $187.63 | $32.98 | $48.9 | -$0.02 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $111.63 | -$40.62 | $20.79 | -$34.77 |
News
Fundamentals
| Market cap | $116.75M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 48.85M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$104.16M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -1.12 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.13 |
|---|---|
| ROA | -45.49% |
| ROE | N/A |
| Debt/Equity | 0.07 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 8.11 |
| Quick ratio | N/A |